A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis

Pietrzak, Anna; Kalinowska-Łyszczarz, Alicja; Osztynowicz, Krystyna; Khamidulla, A; Kozubski, Wojciech; Michalak, Sławomir

doi:10.17219/acem/121063

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Many studies have been conducted to find specific biomarkers related to IFNβ therapy, however, these studies are generally related to the long-term use (>6 months) of the drug. [18][19][20][21][22][23] In our study, the short-term effects of IFNβ on MS patients were investigated.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, biomarkers and individual therapy methods that allow reliable prediction of treatment response before the initiation of therapy are still lacking 18 . Many studies have been conducted to find specific biomarkers related to IFN‐β therapy, however, these studies are generally related to the long‐term use (>6 months) of the drug 18‐23 . In our study, the short‐term effects of IFN‐β on MS patients were investigated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CD4+ and CD25+ T‐cell response to short‐time interferon‐beta therapy on IL10, IL23A and FOXP3 genes in multiple sclerosis patients

et al. 2021

View full text Add to dashboard Cite

Aim of the Study: Interferon-beta (IFNβ), multiple sclerosis (MS) drug for years, does not have therapeutic effects on each patient. Yet, a considerable portion has experienced no therapeutic response to IFNβ. Therefore, it is necessary to determine disease-specific biomarkers that affect drug response. Here, we aimed to determine the effects of interleukin 10 (IL10) and 23 (IL23A), as well as forkhead box P3 (FOXP3) genes on MS after IFNβ therapy.Materials and Methods: Peripheral blood mononuclear cells (PBMCs) of 42 MS patients were isolated to obtain CD4+ and CD25+ T cells. Both cell types were characterised by flow cytometry. To determine optimum drug concentration of IFNβ, cytotoxicity assays were assessed on each cell type for 4, 16, 24 and 48 hours respectively. Then, cells were cultured in the presence of 500 IU/mL of IFNβ. cDNA synthesis was performed after mRNA extraction. RT-PCR was performed to measure gene expressions of IL10, IL23A and FOXP3. Results were evaluated statistically.Results: It was found that the cytotoxic effect of IFNβ was more efficient as the exposure time was expanded regardless of drug concentration. Moreover, CD25+ T lymphocytes were more resistant to IFNβ. IL23A was down-regulated, whereas FOXP3 was up-regulated at 48 hours in CD4+ T cells. For CD25+ T cells, the graded increase in FOXP3 was obtained while IL10 expression was gradually decreased throughout the drug intake. Conclusion:Although a considerable change in expression was obtained, the longterm IFNβ effect on both genes and cells should be determined by follow-up at least a year. What's knownIFNβ reduces the number of episodes and slows down the progression of disability in MS patients. However, the expected therapeutic response has not been experienced in the majority How to cite this article:

show abstract